These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15909959)

  • 21. Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria.
    Pratt-Riccio LR; Lima-Junior JC; Carvalho LJ; Theisen M; Espíndola-Mendes EC; Santos F; Oliveira-Ferreira J; Goldberg AC; Daniel-Ribeiro CT; Banic DM
    Am J Trop Med Hyg; 2005 Dec; 73(6):1096-103. PubMed ID: 16354819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children.
    Okech B; Mujuzi G; Ogwal A; Shirai H; Horii T; Egwang TG
    Am J Trop Med Hyg; 2006 Feb; 74(2):191-7. PubMed ID: 16474069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Looking for parasitic infection and disease: the Plasmodium falciparum malaria model.
    Pica R; Castellano C
    Clin Ter; 2005; 156(3):131-4. PubMed ID: 16048034
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccinating with the genome: a Sisyphean task?
    Coppel RL
    Trends Parasitol; 2009 May; 25(5):205-12. PubMed ID: 19359219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Perspectives in vaccination against malaria].
    Ambroise-Thomas P
    Bull Acad Natl Med; 1985 Apr; 169(4):541-7. PubMed ID: 3902162
    [No Abstract]   [Full Text] [Related]  

  • 26. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
    Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G
    Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
    Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malaria risk: estimating clinical episodes of malaria.
    Nahlen BL; Korenromp EL; Miller JM; Shibuya K
    Nature; 2005 Sep; 437(7056):E3; discussion E4-5. PubMed ID: 16148888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME; Patarroyo MA
    Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising functional readouts of immunity in a blood-stage malaria vaccine trial.
    Crabb BS; Beeson JG
    PLoS Med; 2005 Nov; 2(11):e380. PubMed ID: 16266219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
    Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
    Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of human vaccine research and development: malaria.
    Girard MP; Reed ZH; Friede M; Kieny MP
    Vaccine; 2007 Feb; 25(9):1567-80. PubMed ID: 17045367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Perspectives and challenges of malaria vaccine. Why we must do more].
    Leroy O
    Bull Acad Natl Med; 2007 Oct; 191(7):1249-59; discussion 1259-60. PubMed ID: 18447047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malaria vaccines: immunity, models and monoclonal antibodies.
    Hviid L; Barfod L
    Trends Parasitol; 2008 Sep; 24(9):392-5. PubMed ID: 18675589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic diversity and population history of Plasmodium falciparum and Plasmodium vivax.
    Joy DA; Mu J; Jiang H; Su X
    Parassitologia; 2006 Dec; 48(4):561-6. PubMed ID: 17688177
    [No Abstract]   [Full Text] [Related]  

  • 36. Malaria vaccines. The shape of things to come.
    Cox FE
    Nature; 1988 Jun; 333(6175):702. PubMed ID: 3290680
    [No Abstract]   [Full Text] [Related]  

  • 37. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
    Hermsen CC; Verhage DF; Telgt DS; Teelen K; Bousema JT; Roestenberg M; Bolad A; Berzins K; Corradin G; Leroy O; Theisen M; Sauerwein RW
    Vaccine; 2007 Apr; 25(15):2930-40. PubMed ID: 16914240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area.
    Moormann AM; John CC; Sumba PO; Tisch D; Embury P; Kazura JW
    Am J Trop Med Hyg; 2006 Apr; 74(4):585-90. PubMed ID: 16606988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional genomics, new tools in malaria research.
    Di Girolamo F; Raggi C; Bultrini E; Lanfrancotti A; Silvestrini F; Sargiacomo M; Birago C; Pizzi E; Alano P; Ponzi M
    Ann Ist Super Sanita; 2005; 41(4):469-77. PubMed ID: 16569915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccination against malaria].
    Jakobsen PH; Jepsen S
    Ugeskr Laeger; 1988 Feb; 150(5):271-2. PubMed ID: 3291353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.